Companies in #IRAK4-driven Inflammation
Found 1 company operating in this sector.
Evommune is a US clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company's pipeline is led by EVO101, an IRAK4 inhibitor in Phase 2 for chronic spontaneous urticaria and other inflammatory skin conditions, alongside additional earlier-stage programs. Evommune raised a $115M Series C to advance the pipeline.